DE69936638D1 - Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel - Google Patents

Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel

Info

Publication number
DE69936638D1
DE69936638D1 DE69936638T DE69936638T DE69936638D1 DE 69936638 D1 DE69936638 D1 DE 69936638D1 DE 69936638 T DE69936638 T DE 69936638T DE 69936638 T DE69936638 T DE 69936638T DE 69936638 D1 DE69936638 D1 DE 69936638D1
Authority
DE
Germany
Prior art keywords
igf
buffer
injectable formulations
formulations included
containing injectable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69936638T
Other languages
English (en)
Other versions
DE69936638T2 (de
Inventor
Bret A Shirley
Maninder S Hora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of DE69936638D1 publication Critical patent/DE69936638D1/de
Application granted granted Critical
Publication of DE69936638T2 publication Critical patent/DE69936638T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69936638T 1998-04-03 1999-04-02 IGF-enthaltende injizierbare Formulierungen, enthaltend Succinat als Puffermittel Expired - Fee Related DE69936638T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8000898P 1998-04-03 1998-04-03
US80008P 1998-04-03
PCT/US1999/007531 WO1999051272A1 (en) 1998-04-03 1999-04-02 Injectable igf-formulations containing succinate as buffering agent

Publications (2)

Publication Number Publication Date
DE69936638D1 true DE69936638D1 (de) 2007-09-06
DE69936638T2 DE69936638T2 (de) 2008-05-21

Family

ID=22154445

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69936638T Expired - Fee Related DE69936638T2 (de) 1998-04-03 1999-04-02 IGF-enthaltende injizierbare Formulierungen, enthaltend Succinat als Puffermittel

Country Status (10)

Country Link
US (1) US20070249522A1 (de)
EP (1) EP1069912B1 (de)
JP (1) JP2002510653A (de)
AT (1) ATE367828T1 (de)
AU (1) AU3473999A (de)
DE (1) DE69936638T2 (de)
DK (1) DK1069912T3 (de)
ES (1) ES2288018T3 (de)
PT (1) PT1069912E (de)
WO (1) WO1999051272A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1491208E (pt) 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
EP1423509A2 (de) 2001-08-30 2004-06-02 Stem Cell Therapeutics Inc. Differenzierung von neuralen stammzellen und therapeutische anwendung
EP1430114B1 (de) 2001-09-14 2012-01-18 Stem Cell Therapeutics Inc. Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
AR036402A1 (es) * 2001-09-18 2004-09-08 Stem Cell Therapeutics Inc Efecto de la hormona de crecimiento y de igf-1 sobre celulas madre neuronales.
AU2003250705A1 (en) 2002-07-31 2004-02-16 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
SI1599222T1 (sl) 2003-01-08 2009-08-31 Novartis Vaccines & Diagnostic Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja
US7534765B2 (en) 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
US11097023B1 (en) * 2020-07-02 2021-08-24 Par Pharmaceutical, Inc. Pre-filled syringe containing sugammadex

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080879B1 (de) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Stabilisiertes Interferon enthaltende pharmazeutische Zusammensetzung
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
EP0284249A1 (de) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Gefriergetrocknete Lymphokin-Zusammensetzung
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
DE68907066T2 (de) * 1988-01-29 1993-12-16 Koken Kk Verbesserte Formulierungen mit kontrollierter Abgabe.
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
NZ262634A (en) * 1993-02-23 1997-02-24 Genentech Inc Stabilizing polypeptides against degradation by organic solvents by admixing the peptide with trehalose or mannitol
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US6511811B1 (en) * 1995-06-07 2003-01-28 The Regents Of The University Of California Protein kinase C antagonist related to insulin receptor
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
DE19825736C2 (de) * 1997-06-11 2003-09-18 Hyundai Electronics Ind Verfahren zum Bilden eines Kondensators einer Halbleitervorrichtung
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta

Also Published As

Publication number Publication date
PT1069912E (pt) 2007-09-14
ES2288018T3 (es) 2007-12-16
AU3473999A (en) 1999-10-25
EP1069912A1 (de) 2001-01-24
EP1069912B1 (de) 2007-07-25
WO1999051272A1 (en) 1999-10-14
JP2002510653A (ja) 2002-04-09
DK1069912T3 (da) 2007-11-12
DE69936638T2 (de) 2008-05-21
ATE367828T1 (de) 2007-08-15
US20070249522A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
CO5090908A1 (es) Procedimiento para administrar peptidos insulinotropicos
EA200000629A1 (ru) Стабилизированные растворы терипаратида
RS105704A (sr) Kiseli preparati insulina sa poboljšanom stabilnošću
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
HK1054918A1 (en) Compounds and compositions for delivering active agents
TWI262925B (en) GLP-1 analogues
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
HK1036970A1 (en) Compounds and compositions for delivering active agents.
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
ATE270898T1 (de) Stabile igf/igfbp pharmazeutische formulierungen
IS6750A (is) Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
DE69936638D1 (de) Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
ATE287707T1 (de) Injizierbare propofol-formulierungen
BR9811094A (pt) Agente terapêutico para tumores linfáticos
NO20045507L (no) Injiserbare faste hyaluronsyrebaerere for levering av osteogene proteiner
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
NO2019032I1 (no) Treosulfan
RS50046B (sr) Farmaceutske kompozicije tizoksanida i nitazoksanida
NO20034504L (no) Erytropoietin forbedrer in vivo kjemoterapiindusert toksisitet
ES2174838T3 (es) Metodo para aumentar la absorcion del intestino.
MXPA05009135A (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
ATE245028T1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
EA199901116A1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион
BR0107544A (pt) Composição de promoção de secreção de bile

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: SHIRLEY, BRET, EMERYVILLE, CA, US

Inventor name: HORA, MANINDER, EMERYVILLE, CA, US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee